FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021838368> ?p ?o ?g. }

• W3021838368 endingPage "104872" @default.
• W3021838368 startingPage "104872" @default.
• W3021838368 abstract "The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I2 = 81.3%), remarkably ameliorate clinical improvement (RR 1.52, 95% CI 1.05-2.19) and radiographical improvement (RR 1.62, 95% CI 1.11-2.36, I 2 = 11.0 %), without manifesting clear effect on virological eradication, incidence of ARDS, intubation, and AEs. Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). The lopinavir/ritonavir-based combination showed superior virological eradication and radiographical improvement with reduced rate of ARDS. Likewise, hydroxychloroquine improved radiographical result. For safety, ribavirin could induce more bradycardia, anemia and transaminitis. Meanwhile, hydroxychloroquine could increase AEs rate especially diarrhea. Overall, the quality of evidence on most outcomes were very low. In conclusion, although we could not draw a clear conclusion for the recommendation of potential therapies for COVID-19 considering the very low quality of evidence and wide heterogeneity of interventions and indications, our results may help clinicians to comprehensively understand the advantages and drawbacks of each anti-coronavirus agents on efficacy and safety profiles. Lopinavir/ritonavir combinations might observe better virological eradication capability than other anti-coronavirus agents. Conversely, ribavirin might cause more safety concerns especially bradycardia. Thus, large RCTs objectively assessing the efficacy of antiviral therapies for SARS-CoV-2 infections should be conducted with high priority." @default.
• W3021838368 created "2020-05-13" @default.
• W3021838368 creator A5009043001 @default.
• W3021838368 creator A5015818607 @default.
• W3021838368 creator A5020588717 @default.
• W3021838368 creator A5020616981 @default.
• W3021838368 creator A5026252747 @default.
• W3021838368 creator A5028653401 @default.
• W3021838368 creator A5045438149 @default.
• W3021838368 creator A5049136138 @default.
• W3021838368 creator A5054172647 @default.
• W3021838368 creator A5062429074 @default.
• W3021838368 date "2020-07-01" @default.
• W3021838368 modified "2023-10-11" @default.
• W3021838368 title "Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis" @default.
• W3021838368 cites W2022898511 @default.
• W3021838368 cites W2050828759 @default.
• W3021838368 cites W2073298097 @default.
• W3021838368 cites W2095807050 @default.
• W3021838368 cites W2098155634 @default.
• W3021838368 cites W2098728713 @default.
• W3021838368 cites W2098923148 @default.
• W3021838368 cites W2102390620 @default.
• W3021838368 cites W2103741738 @default.
• W3021838368 cites W2112857740 @default.
• W3021838368 cites W2125435699 @default.
• W3021838368 cites W2139603860 @default.
• W3021838368 cites W2149865974 @default.
• W3021838368 cites W2150120685 @default.
• W3021838368 cites W2725497285 @default.
• W3021838368 cites W2953402028 @default.
• W3021838368 cites W2955112665 @default.
• W3021838368 cites W3001456238 @default.
• W3021838368 cites W3003322996 @default.
• W3021838368 cites W3004280078 @default.
• W3021838368 cites W3005212621 @default.
• W3021838368 cites W3008131087 @default.
• W3021838368 cites W3009577418 @default.
• W3021838368 cites W3010930696 @default.
• W3021838368 cites W3012379316 @default.
• W3021838368 cites W3014203610 @default.
• W3021838368 cites W3014594122 @default.
• W3021838368 cites W3165656738 @default.
• W3021838368 doi "https://doi.org/10.1016/j.phrs.2020.104872" @default.
• W3021838368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7192121" @default.
• W3021838368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32360583" @default.
• W3021838368 hasPublicationYear "2020" @default.
• W3021838368 type Work @default.
• W3021838368 sameAs 3021838368 @default.
• W3021838368 citedByCount "74" @default.
• W3021838368 countsByYear W30218383682020 @default.
• W3021838368 countsByYear W30218383682021 @default.
• W3021838368 countsByYear W30218383682022 @default.
• W3021838368 countsByYear W30218383682023 @default.
• W3021838368 crossrefType "journal-article" @default.
• W3021838368 hasAuthorship W3021838368A5009043001 @default.
• W3021838368 hasAuthorship W3021838368A5015818607 @default.
• W3021838368 hasAuthorship W3021838368A5020588717 @default.
• W3021838368 hasAuthorship W3021838368A5020616981 @default.
• W3021838368 hasAuthorship W3021838368A5026252747 @default.
• W3021838368 hasAuthorship W3021838368A5028653401 @default.
• W3021838368 hasAuthorship W3021838368A5045438149 @default.
• W3021838368 hasAuthorship W3021838368A5049136138 @default.
• W3021838368 hasAuthorship W3021838368A5054172647 @default.
• W3021838368 hasAuthorship W3021838368A5062429074 @default.
• W3021838368 hasBestOaLocation W30218383681 @default.
• W3021838368 hasConcept C120665830 @default.
• W3021838368 hasConcept C121332964 @default.
• W3021838368 hasConcept C126322002 @default.
• W3021838368 hasConcept C159047783 @default.
• W3021838368 hasConcept C167135981 @default.
• W3021838368 hasConcept C168563851 @default.
• W3021838368 hasConcept C177713679 @default.
• W3021838368 hasConcept C197934379 @default.
• W3021838368 hasConcept C201903717 @default.
• W3021838368 hasConcept C2522874641 @default.
• W3021838368 hasConcept C2776348555 @default.
• W3021838368 hasConcept C2776408679 @default.
• W3021838368 hasConcept C2776478404 @default.
• W3021838368 hasConcept C2776525042 @default.
• W3021838368 hasConcept C2777714996 @default.
• W3021838368 hasConcept C2779123688 @default.
• W3021838368 hasConcept C2779134260 @default.
• W3021838368 hasConcept C2780040827 @default.
• W3021838368 hasConcept C3008058167 @default.
• W3021838368 hasConcept C44249647 @default.
• W3021838368 hasConcept C524204448 @default.
• W3021838368 hasConcept C61511704 @default.
• W3021838368 hasConcept C71924100 @default.
• W3021838368 hasConcept C72563966 @default.
• W3021838368 hasConcept C82789193 @default.
• W3021838368 hasConcept C95190672 @default.
• W3021838368 hasConceptScore W3021838368C120665830 @default.
• W3021838368 hasConceptScore W3021838368C121332964 @default.
• W3021838368 hasConceptScore W3021838368C126322002 @default.
• W3021838368 hasConceptScore W3021838368C159047783 @default.
• W3021838368 hasConceptScore W3021838368C167135981 @default.
• W3021838368 hasConceptScore W3021838368C168563851 @default.

• next